Zosano Pharma

Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FREMONT, Calif., Aug.  18, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that develops and commercializes innovative therapies for patients addressing unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines.

Zosano Pharma Announces Agreement to Collaborate with Mitsubishi Tanabe Pharma Corporation

Agreement outlines commercialization and distribution execution strategy upon FDA approval

Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™

FREMONT, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020, as well as recent business highlights.

Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update

FREMONT, Calif., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 3:00 pm ET.

Zosano Pharma to Present at the BTIG Biotechnology Conference 2020

FREMONT, Calif., June  13, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual oral presentation on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform.

Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeti

FREMONT, Calif., June  11, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced a change in the format of its Annual Meeting of Stockholders (“Annual Meeting”) from in-person to virtual-only. Due to the public health impact of the coronavirus (COVID-19) pandemic and to support the health and well-being of our stockholders, employees and their families, the Company will hold its Annual Meeting in a virtual meeting format only, via webcast. As previously announced, the Annual Meeting will be held on Thursday, June 25, 2020 at 8:30 a.m. Pacific time.

Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders

FREMONT, Calif., May  14, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2020, as well as recent business highlights.

Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update

FREMONT, Calif., May  01, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO). Ms. Matthews, who previously served as interim CFO, will be responsible for leading the finance and accounting departments.

Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer

FREMONT, Calif., March  06, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 11,903,506 shares of its common stock and warrants to purchase up to 11,903,506 shares of its common stock, at a combined purchase price of $0.9275 per share and associated warrant, for aggregate gross proceeds of approximately $11 million. The warrants have an exercise price of $0.8025 per share, are immediately exercisable and will expire five years from the date of issuance.

Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market

FREMONT, Calif., March  05, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the issuance and sale in a registered direct offering of 11,903,506 shares of its common stock and warrants to purchase up to 11,903,506 shares of its common stock, at a combined purchase price of $0.9275 per share and associated warrant, for aggregate gross proceeds of approximately $11 million in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $0.8025 per share, are immediately exercisable and will expire five years from the date of issuance.

Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market

FREMONT, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Qtrypta™ for filing and substantive review.

Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine

FREMONT, Calif., Feb.  12, 2020  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN)  (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of (i) 10,146,154 Class A Units, each consisting of one share of common stock and one Series C Warrant to purchase one share of common stock, at a public offering price of $0.65 per Class A Unit, and (ii) 2,161,539 Class B Units, each consisting of one Series D Pre-Funded Warrant to purchase one share of common stock and one Series C Warrant to purchase one share of common stock, at a public offering price of $0.6499 per Class B Unit.  The Series C Warrants have an exercise price of $0.65 per share, are immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,846,153 shares of common stock and/or additional Series C Warrants to purchase up to 1,846,153 shares of common stock.  

Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants

FREMONT, Calif., Dec.  23, 2019  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application (“NDA”) for Qtrypta™ to the U.S. Food and Drug Administration (“FDA”) for the acute treatment of migraine.

Zosano Announces FDA Submission of New Drug Application for Qtrypta

FREMONT, Calif., Nov.  27, 2019  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate of 2,181,034 shares of its common stock at a price of $1.45 per share in a registered direct offering.

Zosano Announces Pricing of Registered Direct Offering

Zosano Pharma Corp (ZSAN) CEO Steven Lo on Q3 2019 Results - Earnings Call Transcript

Zosano plans to submit NDA for Qtrypta in December 2019 Zosano plans to submit NDA for Qtrypta in December 2019

Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™

Advances Second Late Stage Program for ADAM Microneedle Technology Advances Second Late Stage Program for ADAM Microneedle Technology

Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache

Steven Lo appointed President and CEO; John Walker remains as Chairman of the Board Steven Lo appointed President and CEO; John Walker remains as Chairman of the Board

Zosano Pharma Announces CEO Transition

FREMONT, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview at the 2019 Cantor Global Healthcare Conference in New York on Thursday, October 3, 2019 at 10:05 am ET.

Zosano Pharma to Present at the Cantor Global Healthcare Conference

FREMONT, Calif., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development.

Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

- Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine -

Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society

FREMONT, Calif., Aug.  23, 2019  (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress of the International Headache Society (IHC). The meeting will take place September 5-8, 2019 in Dublin, Ireland.

Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

Zosano Pharma Corporation (ZSAN) CEO John Walker on Q2 2019 Results - Earnings Call Transcript

Zosano Pharma Corp (NASDAQ: ZSAN) shared positive results of Migraine-ACT scores for Qtrypta therapy.

Zosano Pharma Presents Positive Migraine-ACT Results

FDA approval of ZSAN's best-in-class migraine treatment is largely de-risked due to superb P3 results. Side effects were mostly mild and transient or related to the already approved zolmitriptan.

News for Zosano Pharma Stock (ZSAN)